S Matthijs Boekholdt

List of Publications by Citations

240 papers	18,691 citations	61 h-index	134 g-index
256 ext. papers	21,374 ext. citations	7.8 avg, IF	5.95 L-index

#	Paper	IF	Citations
240	Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*, **2010**, 466, 707-13	50.4	2742
239	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nature Genetics*, **2011**, 43, 333-8	36.3	1394
238	Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation*, **2007**, 115, 450-8	16.7	1001
237	Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet, The*, **2010**, 375, 1634-9	40	520
236	Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1302-9	27.4	512
235	Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. *Journal of the American College of Cardiology*, **2007**, 50, 159-65	15.1	483
234	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nature Genetics*, **2011**, 43, 1131-8	36.3	415
233	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *Journal of the American College of Cardiology*, **2014**, 64, 485-94	15.1	372
232	Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation*, **2008**, 117, 3002-9	16.7	357
231	Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. *Circulation*, **2007**, 116, 2933-43	16.7	352
230	Genetic variants influencing circulating lipid levels and risk of coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2264-76	9.4	318
229	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 507-13	18.1	300
228	Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes*, **2011**, 60, 2624-34	0.9	285
227	Lipid-related markers and cardiovascular disease prediction. *JAMA - Journal of the American Medical Association*, **2012**, 307, 2499-506	27.4	271
226	Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. *Circulation*, **2005**, 111, 278-87	16.7	266
225	High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. *Journal of the American College of Cardiology*, **2008**, 51, 634-42	15.1	264
224	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. *European Heart Journal*, **2014**, 35, 960-8	9.5	222

223	Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. *Journal of the American College of Cardiology*, **2009**, 55, 35-41	15.1	220
222	Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. *Journal of the American College of Cardiology*, **2007**, 49, 547-53	15.1	198
221	Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. *Circulation*, **2003**, 107, 2416-21	16.7	198
220	Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. *Circulation*, **2004**, 110, 1418-23	16.7	188
219	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. *Lancet, The*, **2010**, 376, 333-9	40	178
218	High-density lipoprotein particle size and concentration and coronary risk. *Annals of Internal Medicine*, **2009**, 150, 84-93	8	167
217	Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. *Circulation*, **2001**, 104, 3063-8	16.7	164
216	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. *Nature Communications*, **2014**, 5, 5068	17.4	160
215	Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. *Circulation: Cardiovascular Genetics*, **2014**, 7, 304-10		160
214	Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. *Journal of the American College of Cardiology*, **2018**, 71, 711-722	15.1	158
213	IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 1503-8	9.4	150
212	Lipid parameters for measuring risk of cardiovascular disease. *Nature Reviews Cardiology*, **2011**, 8, 197-206	14.8	144
211	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. *Circulation*, **2013**, 128, 1504-12	16.7	135
210	C-reactive protein is a mediator of cardiovascular disease. *European Heart Journal*, **2010**, 31, 2087-91	9.5	135
209	C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. *Atherosclerosis*, **2006**, 187, 415-22	3.1	134
208	Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. *Journal of the American College of Cardiology*, **2013**, 61, 148-52	15.1	130
207	The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. *Cmaj*, **2010**, 182, 1427-32	3.5	120
206	Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. *Journal of the American College of Cardiology*, **2010**, 56, 946-55	15.1	120

205	Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. *Journal of Lipid Research*, **2003**, 44, 1080-93	6.3	120
204	Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. *Annals of Internal Medicine*, **2007**, 146, 640-8	8	116
203	Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. *Clinical Endocrinology*, **2010**, 72, 404-10	3.4	115
202	Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. *Circulation*, **2012**, 125, 1979-87	16.7	114
201	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. *Circulation*, **2016**, 134, 1419-1429	16.7	104
200	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. *Journal of the American College of Cardiology*, **2019**, 73, 2150-2162	15.1	97
199	Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 3058-65	9.4	97
198	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. *Journal of Lipid Research*, **2011**, 52, 1829-36	6.3	96
197	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. *Journal of the American College of Cardiology*, **2013**, 62, 1966-1976	15.1	91
196	PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. *Circulation*, **2010**, 121, 2284-93	16.7	90
195	Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 1177-83	9.4	89
194	Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. *Circulation*, **2007**, 116, 2029-35	16.7	88
193	HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *Atherosclerosis*, **2009**, 206, 276-81	3.1	86
192	Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. *Journal of Lipid Research*, **2007**, 48, 139-44	6.3	86
191	Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 839-46	9.4	85
190	Inherited disorders of HDL metabolism and atherosclerosis. *Current Opinion in Lipidology*, **2005**, 16, 139-45	4.4	84
189	Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. *European Heart Journal*, **2011**, 32, 336-44	9.5	80
188	Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. *Heart*, **2010**, 96, 1985-9	5.1	79

187	Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. *Circulation*, **2010**, 121, 52-62	16.7	76
186	Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. *Journal of Lipid Research*, **2006**, 47, 2064-70	6.3	76
185	Arterial thrombosis and the role of thrombophilia. *Seminars in Thrombosis and Hemostasis*, **2007**, 33, 588-96	3.9	76
184	Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. *Circulation*, **2010**, 122, 470-7	16.7	75
183	ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 2319-25	9.4	75
182	Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. *American Journal of Medicine*, **2004**, 117, 390-7	2.4	73
181	On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). *Journal of the American College of Cardiology*, **2012**, 59, 1521-8	15.1	72
180	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. *Circulation*, **2018**, 138, 770-781	16.7	65
179	Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 975-80	9.4	61
178	Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. *Journal of Internal Medicine*, **2007**, 262, 678-89	10.8	61
177	The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?. *Diabetes*, **2014**, 63, 332-342	0.9	60
176	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. *European Heart Journal*, **2018**, 39, 2589-2596	9.5	56
175	Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 706-15	9.4	56
174	Physical inactivity, abdominal obesity and risk of coronary heart disease in apparently healthy men and women. *International Journal of Obesity*, **2010**, 34, 340-7	5.5	55
173	Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 2345-50	9.4	54
172	Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 637-42	9.4	54
171	Impact of physical activity on the risk of cardiovascular disease in middle-aged and older adults: EPIC Norfolk prospective population study. *European Journal of Preventive Cardiology*, **2018**, 25, 200-208	3.9	54
170	Habitual chocolate consumption and risk of cardiovascular disease among healthy men and women. *Heart*, **2015**, 101, 1279-87	5.1	53

169	The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2277-82	9.4	53
168	Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. *Journal of the American College of Cardiology*, **2012**, 59, 1778-84	15.1	51
167	Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 255-60	5.6	51
166	Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. *International Journal of Cardiology*, **2017**, 231, 155-161	3.2	50
165	Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. *Current Opinion in Lipidology*, **2015**, 26, 502-10	4.4	50
164	Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. *Journal of Lipid Research*, **2010**, 51, 416-21	6.3	50
163	Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC-Norfolk study. *International Journal of Cardiology*, **2013**, 168, 3550-5	3.2	49
162	Bayesian meta-analysis of genetic association studies with different sets of markers. *American Journal of Human Genetics*, **2008**, 82, 859-72	11	49
161	Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events?. *Archives of Internal Medicine*, **2008**, 168, 1209-16		49
160	CETP gene variation: relation to lipid parameters and cardiovascular risk. *Current Opinion in Lipidology*, **2004**, 15, 393-8	4.4	48
159	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals. *Circulation Research*, **2019**, 125, 773-782	15.7	47
158	Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease: The RESPONSE-2 Trial. *Journal of the American College of Cardiology*, **2017**, 70, 318-327	15.1	47
157	Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. *Human Genetics*, **2003**, 113, 417-25	6.3	47
156	Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, e24-7	9.4	46
155	The role of non-HDL cholesterol in risk stratification for coronary artery disease. *Current Atherosclerosis Reports*, **2012**, 14, 130-4	6	45
154	Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. *European Heart Journal*, **2007**, 28, 2770-7	9.5	44
153	Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease. *European Heart Journal Cardiovascular Imaging*, **2013**, 14, 642-9	4.1	41
152	Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. *Clinical Genetics*, **2006**, 69, 263-70	4	41

151	Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study. *British Journal of Nutrition*, **2006**, 96, 516-22	3.6	41
150	Role of CETP inhibitors in the treatment of dyslipidemia. *Current Opinion in Lipidology*, **2004**, 15, 631-6	4.4	40
149	Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2011**, 18, 209-17		39
148	Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. *Atherosclerosis*, **2017**, 256, 47-52	3.1	38
147	The interleukin-6 pathway and atherosclerosis. *Lancet, The*, **2012**, 379, 1176-8	40	38
146	Aortic valve stenosis and aortic diameters determine the extent of increased wall shear stress in bicuspid aortic valve disease. *Journal of Magnetic Resonance Imaging*, **2018**, 48, 522-530	5.6	37
145	Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. *PLoS ONE*, **2009**, 4, e6809	3.7	37
144	Ideal cardiovascular health and risk of cardiovascular events in the EPIC-Norfolk prospective population study. *European Journal of Preventive Cardiology*, **2016**, 23, 986-94	3.9	36
143	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 1206-1212	9.4	35
142	Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions. *Heart*, **2013**, 99, 188-94	5.1	35
141	Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. *Atherosclerosis*, **2010**, 211, 558-64	3.1	35
140	Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. *Circulation: Cardiovascular Genetics*, **2009**, 2, 389-95		35
139	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nature Genetics*, **2021**, 53, 128-134	36.3	35
138	C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2888-94	9.4	34
137	High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. *Circulation*, **2013**, 127, 2485-93	16.7	34
136	Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. *Heart*, **2009**, 95, 1682-7	5.1	34
135	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. *Heart*, **2015**, 101, 356-62	5.1	33
134	Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk. *Heart*, **2016**, 102, 63-8	5.1	32

133	Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). *American Journal of Cardiology*, **2011**, 108, 367-73	3	32
132	High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. *Congenital Heart Disease*, **2013**, 8, 520-6	3.1	29
131	Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. *Clinical Chemistry*, **2010**, 56, 789-98	5.5	29
130	Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *International Journal of Cardiology*, **2010**, 143, 399-404	3.2	29
129	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 92-100	4.1	29
128	Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms. *Journal of the American College of Cardiology*, **2017**, 69, 1513-1515	15.1	28
127	Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus. *Heart Rhythm*, **2016**, 13, 905-12	6.7	28
126	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. *Journal of Medical Genetics*, **2016**, 53, 835-845	5.8	28
125	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. *Journal of Clinical Lipidology*, **2018**, 12, 130-136	4.9	27
124	Smoking cessation after an acute coronary syndrome: immediate quitters are successful quitters. *Netherlands Heart Journal*, **2015**, 23, 600-7	2.2	26
123	Surgical versus percutaneous treatment of aortic coarctation: new standards in an era of transcatheter repair. *Expert Review of Cardiovascular Therapy*, **2012**, 10, 1517-31	2.5	26
122	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. *European Heart Journal*, **2020**, 41, 3998-4007	9.5	26
121	Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study. *Atherosclerosis*, **2010**, 209, 261-5	3.1	25
120	Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and women. *Psychosomatic Medicine*, **2008**, 70, 850-5	3.7	25
119	Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy of Fallot. *Circulation*, **2018**, 137, 1463-1471	16.7	25
118	Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study. *European Heart Journal*, **2016**, 37, 880-9	9.5	24
117	Lipid assessment, metabolic syndrome and coronary heart disease risk. *European Journal of Clinical Investigation*, **2010**, 40, 1081-93	4.6	24
116	Effective components of nurse-coordinated care to prevent recurrent coronary events: a systematic review and meta-analysis. *Heart*, **2016**, 102, 50-6	5.1	23

115	Added value of hybrid myocardial perfusion SPECT and CT coronary angiography in the diagnosis of coronary artery disease. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1281-8	4.1	23
114	Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. *European Journal of Clinical Investigation*, **2013**, 43, 1009-15	4.6	23
113	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. *Journal of Lipid Research*, **2016**, 57, 697-705	6.3	22
112	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?. *Circulation*, **2015**, 132, 433-40	16.7	21
111	Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). *American Journal of Cardiology* , **2014**, 113, 1378-82	3	21
110	Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. *Circulation: Cardiovascular Genetics*, **2014**, 7, 144-50		21
109	Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2204-9	15.4	20
108	Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events. *American Heart Journal*, **2004**, 147, 181-6	4.9	20
107	Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations. *Journal of the American College of Cardiology*, **2016**, 67, 2313-2315	15.1	20
106	Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 43-48	9.4	19
105	Genetic and In Vitro Inhibition of and Calcific Aortic Valve Stenosis. *JACC Basic To Translational Science*, **2020**, 5, 649-661	8.7	18
104	Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. *Journal of Clinical Lipidology*, **2018**, 12, 597-603.e1	4.9	18
103	Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification. *JAMA Cardiology*, **2019**, 4, 620-627	16.2	17
102	C-Reactive Protein Identifies Low-Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer-Norfolk Prospective Population Study. *Journal of the American Heart Association*, **2016**, 5,	6	17
101	C-reactive protein and cardiovascular risk: more fuel to the fire. *Lancet, The*, **2010**, 375, 95-6	40	17
100	The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. *Circulation: Cardiovascular Genetics*, **2012**, 5, 51-7		17
99	Human Cardiac P-MR Spectroscopy at 3 Tesla Cannot Detect Failing Myocardial Energy Homeostasis during Exercise. *Frontiers in Physiology*, **2017**, 8, 939	4.6	16
98	Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 1460-6	9.4	16

97	Rimonabant: obituary for a wonder drug. *Lancet, The*, **2010**, 376, 489-90	40	16
96	Physical activity, C-reactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2006**, 13, 970-6		16
95	PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk. *Circulation: Cardiovascular Genetics*, **2015**, 8, 356-62		15
94	Myocardial infarction with non-obstructive coronary arteries: a focus on vasospastic angina. *Netherlands Heart Journal*, **2019**, 27, 237-245	2.2	14
93	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease-Free Survival, and Mortality Risk: A Mendelian Randomization Analysis. *JAMA Network Open*, **2020**, 3, e200129	10.4	14
92	Advanced cardiac MRI techniques for evaluation of left-sided valvular heart disease. *Journal of Magnetic Resonance Imaging*, **2018**, 48, 318-329	5.6	14
91	The Systematic COronary Risk Evaluation (SCORE) in a large UK population: 10-year follow-up in the EPIC-Norfolk prospective population study. *European Journal of Preventive Cardiology*, **2015**, 22, 119-26	3.9	14
90	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. *Canadian Journal of Cardiology*, **2017**, 33, 343-349	3.8	13
89	CT angiography vs echocardiography for detection of cardiac thrombi in ischemic stroke: a systematic review and meta-analysis. *Journal of Neurology*, **2020**, 267, 1793-1801	5.5	13
88	The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis. *American Heart Journal*, **2018**, 199, 163-169	4.9	13
87	Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and toll-like receptor 4 gene polymorphisms. *Clinical Chemistry*, **2005**, 51, 516-21	5.5	12
86	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. *Heart*, **2018**, 104, 1699-1705	5.1	11
85	Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. *American Journal of Cardiovascular Drugs*, **2020**, 20, 73-80	4	11
84	Four-dimensional flow MRI of stented versus stentless aortic valve bioprostheses. *European Radiology*, **2018**, 28, 257-264	8	11
83	Habitual chocolate consumption and the risk of incident heart failure among healthy men and women. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 722-34	4.5	10
82	Life's simple 7 and calcific aortic valve stenosis incidence in apparently healthy men and women. *International Journal of Cardiology*, **2018**, 269, 226-228	3.2	10
81	Aortic dissection and prophylactic surgery in congenital heart disease. *International Journal of Cardiology*, **2019**, 274, 113-116	3.2	10
80	Community-based comprehensive lifestyle programs in patients with coronary artery disease: Objectives, design and expected results of Randomized Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists 2 trial (RESPONSE 2). *American Heart Journal*, **2015**, 170, 216-22	4.9	9

79	Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. *Journal of the American Heart Association*, **2017**, 6,	6	9
78	Percutaneous treatment of native aortic coarctation in adults. *Netherlands Heart Journal*, **2011**, 19, 436-9	2.2	9
77	Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. *Netherlands Heart Journal*, **2011**, 19, 509-13	2.2	9
76	Tissue factor serum levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2391-6	15.4	9
75	Platypnoea-orthodeoxia syndrome, an underdiagnosed cause of hypoxaemia: four cases and the possible underlying mechanisms. *Netherlands Heart Journal*, **2015**, 23, 539-45	2.2	8
74	Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women: the EPIC-Norfolk Population Study. *Journal of Hypertension*, **2014**, 32, 2224-30; discussion 2230	1.9	8
73	Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model. *BMC Medicine*, **2012**, 10, 158	11.4	8
72	Relationship between atorvastatin dose and the harm caused by torcetrapib. *Journal of Lipid Research*, **2012**, 53, 2436-42	6.3	8
71	Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 261-85	0.9	8
70	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. *Circulation: Cardiovascular*	5.8	8
69	Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies. *JAMA Cardiology*, **2021**, 6, 587-592	16.2	8
68	Impact of cholesterol on proinflammatory monocyte production by the bone marrow. *European Heart Journal*, **2021**, 42, 4309-4320	9.5	8
67	Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis. *JAMA Cardiology*, **2020**, 5, 694-702	16.2	7
66	Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease. *Atherosclerosis*, **2016**, 245, 155-60	3.1	7
65	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. *Structural Heart*, **2018**, 2, 53-57	0.6	7
64	apoB/apoA-I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study. *Journal of the American Heart Association*, **2019**, 8, e013020	6	7
63	Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. *American Heart Journal*, **2021**, 236, 80-86	4.9	7
62	Smoking cessation after nurse-coordinated referral to a comprehensive lifestyle programme in patients with coronary artery disease: a substudy of the RESPONSE-2 trial. *European Journal of Cardiovascular Nursing*, **2019**, 18, 113-121	3.3	7

61	Validation of the Systematic COronary Risk Evaluation - Older Persons (SCORE-OP) in the EPIC-Norfolk prospective population study. *International Journal of Cardiology*, **2019**, 293, 226-230	3.2	6
60	Per-operative stent placement in the right pulmonary artery; a hybrid technique for the management of pulmonary artery branch stenosis at the time of pulmonary valve replacement in adult Fallot patients. *Netherlands Heart Journal*, **2011**, 19, 432-5	2.2	6
59	Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. *Pharmacogenetics and Genomics*, **2010**, 20, 544-52	1.9	6
58	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. *Current Opinion in Cardiology*, **2010**, 25, 622-6	2.1	6
57	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. *Journal of Clinical Lipidology*, **2018**, 12, 1493-1501.e11	4.9	6
56	Body mass index and body fat distribution and new-onset atrial fibrillation: Substudy of the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2019**, 29, 692-700	4.5	5
55	Lifestyle modification in older versus younger patients with coronary artery disease. *Heart*, **2020**, 106, 1066-1072	5.1	5
54	Rates and determinants of progressive aortic valve dysfunction in aortic coarctation. *International Journal of Cardiology*, **2013**, 167, 2841-5	3.2	5
53	Aortic dissection masquerading as a code stroke: A single-centre cohort study. *European Stroke Journal*, **2020**, 5, 56-62	5.6	5
52	Lipoprotein(a) is robustly associated with aortic valve calcium. *Heart*, **2021**, 107, 1422-1428	5.1	5
51	Myocardial fibrosis predicts adverse outcome after MitraClip implantation. *Catheterization and Cardiovascular Interventions*, **2019**, 93, 1146-1149	2.7	5
50	Abnormal blood flow and wall shear stress are present in corrected aortic coarctation despite successful surgical repair. *Journal of Cardiovascular Surgery*, **2019**, 60, 152-154	0.7	4
49	Bileaflet mechanical aortic valves do not alter ascending aortic wall shear stress. *International Journal of Cardiovascular Imaging*, **2019**, 35, 703-710	2.5	4
48	Subclinical effects of long-chain fatty acid □xidation deficiency on the adult heart: A case-control magnetic resonance study. *Journal of Inherited Metabolic Disease*, **2020**, 43, 969-980	5.4	4
47	Outcomes of cardiac surgery after mediastinal radiation therapy: A single-center experience. *Journal of Cardiac Surgery*, **2020**, 35, 612-619	1.3	4
46	A pooled-analysis of age and sex based coronary artery calcium scores percentiles. *Journal of Cardiovascular Computed Tomography*, **2020**, 14, 414-420	2.8	4
45	Unroofed coronary sinus newly diagnosed in adult patients after corrected congenital heart disease. *Netherlands Heart Journal*, **2014**, 22, 240-5	2.2	4
44	Zero coronary calcium in the presence of severe isolated left main stenosis detected by CT coronary angiography in a patient with typical angina and equivocal myocardial perfusion SPECT. *Journal of Nuclear Cardiology*, **2012**, 19, 165-8	2.1	4

43	Reply: To PMID 23219296. *Journal of the American College of Cardiology*, **2013**, 61, 1934	15.1	4
42	Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?. *Clinical Lipidology*, **2011**, 6, 639-651		4
41	Transition from paediatric to adult care of adolescent patients with congenital heart disease: a pathway to optimal care. *Netherlands Heart Journal*, **2016**, 24, 682-690	2.2	4
40	Can stress echocardiography identify patients who will benefit from percutaneous mitral valve repair?. *International Journal of Cardiovascular Imaging*, **2019**, 35, 645-651	2.5	4
39	Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration. *Open Heart*, **2017**, 4, e000607	3	3
38	Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. *Heart*, **2020**, 106, 1407-1412	5.1	3
37	Very low LDL-cholesterol concentrations achieved: which target is next?. *Lancet, The*, **2017**, 390, 1930-1931	40	3
36	Two cases of aorto-right atrial tunnel: clinical presentation, imaging and percutaneous closure. *Netherlands Heart Journal*, **2012**, 20, 509-12	2.2	3
35	Patent ductus arteriosus in adults - indications and possibilities for closure. *Netherlands Heart Journal*, **2011**, 19, 297-300	2.2	3
34	Fully quantitative mapping of abnormal aortic velocity and wall shear stress direction in patients with bicuspid aortic valves and repaired coarctation using 4D flow cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*, **2021**, 23, 9	6.9	3
33	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. *Heart*, **2022**, 108, 61-66	5.1	3
32	Quantification of Mitral Valve Regurgitation from 4D Flow MRI Using Semiautomated Flow Tracking. *Radiology: Cardiothoracic Imaging*, **2020**, 2, e200004	8.3	2
31	Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. *European Heart Journal*, **2013**, 34, 1350-7	9.5	2
30	Response to letter by Balta et al. *International Journal of Cardiology*, **2013**, 169, 89	3.2	2
29	Systolic anterior motion of the tricuspid valve in a patient with hypertrophic obstructive cardiomyopathy. *Interactive Cardiovascular and Thoracic Surgery*, **2017**, 25, 496-497	1.8	2
28	The Dutch SCORE-based risk charts seriously underestimate the risk of cardiovascular disease. *Netherlands Heart Journal*, **2017**, 25, 173-180	2.2	2
27	Common genetic variants do not associate with CAD in familial hypercholesterolemia. *European Journal of Human Genetics*, **2014**, 22, 809-13	5.3	2
26	Usefulness of coronary calcium scoring to myocardial perfusion SPECT in the diagnosis of coronary artery disease in a predominantly high risk population. *International Journal of Cardiovascular Imaging*, **2013**, 29, 677-84	2.5	2

25	A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort. *European Journal of Preventive Cardiology*, **2013**, 20, 98-106	3.9	2
24	Improving risk stratification for cardiovascular disease. *Expert Review of Cardiovascular Therapy*, **2010**, 8, 1091-3	2.5	2
23	Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?. *Current Cardiovascular Risk Reports*, **2009**, 3, 137-143	0.9	2
22	Retrospective Camera-Based Respiratory Gating in Clinical Whole-Heart 4D Flow MRI. *Journal of Magnetic Resonance Imaging*, **2021**, 54, 440-451	5.6	2
21	Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy. *Journal of Magnetic Resonance Imaging*, **2021**, 54, 411-420	5.6	2
20	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003271	5.2	2
19	Effect of Long-Term Low Lipoproteins on Neurocognitive Function. *Journal of the American College of Cardiology*, **2018**, 72, 1176-1177	15.1	1
18	Coronary Artery Disease Affects Symptomatology of Aortic Valve Stenosis. *Journal of the American College of Cardiology*, **2017**, 70, 1103-1104	15.1	1
17	Percutaneous treatment of native aortic coarctation in adults. *Netherlands Heart Journal*, **2012**, 20, 339-40	2.2	1
16	The authors reply. *Heart*, **2013**, 99, 1136-7	5.1	1
15	C-reactive protein measurement and cardiovascular disease Authors' reply. *Lancet, The*, **2010**, 375, 1077-1078	40	1
14	Comprehensive Lipid Profiling Beyond LDL **2011**, 107-118		1
13	Mind the Heart: Electrocardiography-gated cardiac computed tomography-angiography in acute ischaemic stroke-rationale and study design. *European Stroke Journal*, **2020**, 5, 441-448	5.6	1
12	Association between serum secretory phospholipase A2 and risk of ischaemic stroke. *European Journal of Neurology*, **2021**, 28, 3650-3655	6	1
11	Response to "comment on "aldosterone pathway blockade to prevent atrial fibrillation: A systematic review and meta-analysis" by Neefs et al.". *International Journal of Cardiology*, **2017**, 242, 23	3.2	0
10	A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. *Journal of Clinical Lipidology*, **2019**, 13, 492-501	4.9	0
9	Clinical and biological relevance of statin-mediated changes in HDL metabolism. *Current Atherosclerosis Reports*, **2014**, 16, 379	6	0
8	Standardizing the Cardiac Radioablation Targeting Workflow: Enabling Semi-Automated Angulation and Segmentation of the Heart According to the American Heart Association Segmented Model.. *Advances in Radiation Oncology*, **2022**, 7, 100928	3.3	0

7	The impact and challenges of implementing CTCA according to the 2019 ESC guidelines on chronic coronary syndromes: a survey and projection of CTCA services in the Netherlands.. *Insights Into Imaging*, **2021**, 12, 186	5.6	0
6	Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better?. *Journal of the American College of Cardiology*, **2015**, 65, 109	15.1	
5	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al.. *Heart*, **2022**,	5.1	
4	Midline crossing pulmonary vein: right upper lobe dual venous drainage, with partial anomalous venous return of the right lung into a persistent left superior vena cava. *Surgical and Radiologic Anatomy*, **2021**, 1	1.4	
3	Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 4044-4044	2.2	
2	Multimodality Evaluation of a Septal Cystic Cavity and Ventricular Septal Defect in the Setting of Neurocysticercosis and Endocarditis. *Circulation: Cardiovascular Imaging*, **2021**, 14, e011688	3.9	
1	Confirmatory factor analysis including MRI-derived adipose tissues quantification improves associations of metabolic dysregulation to diastolic dysfunction.. *Journal of Diabetes and Its Complications*, **2022**, 36, 108202	3.2	